Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study

Cameron S. Lewis; Greta Joy; Paw Jensen; Allison Barraclough; Nunzio Franco; Dipti Talaulikar; Eliza A. Hawkes; Tarec Christoffer El-Galaly; Diego Villa; Michael Dickinson; John F. Seymour; Chan Y. Cheah

doi:10.1111/bjh.19470

Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study

Cameron S. Lewis, Greta Joy, Paw Jensen, Allison Barraclough, Nunzio Franco, Dipti Talaulikar, Eliza A. Hawkes, Tarec Christoffer El-Galaly, Diego Villa, Michael Dickinson, John F. Seymour, Chan Y. Cheah^*

^*Corresponding author for this work

School of Medicine and Psychology

Research output: Contribution to journal › Article › peer-review

Abstract

Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) accounts for the majority of extra-nodal DLBCL. Even so, literature is lacking on early, localised presentations. We studied a cohort of patients with stage I disease, diagnosed between 2006 and 2018, from six centres between Australia, Canada and Denmark. Our goal was to characterise outcomes, review treatment and investigate the role of interim positron emission tomography (iPET). Thirty-seven eligible patients were identified. The median duration of follow-up was 42.2 months. All received chemoimmunotherapy with 91.9% (n = 34) given rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP). 35.1% (n = 13) underwent consolidative radiotherapy. Eighteen patients were H. pylori positive and 11 had the documentation of H. pylori eradication therapy. The 4-year progression-free survival and overall survival of R-CHOP was 88% (95% CI: 71–95) and 91% (95% CI: 75–97) respectively. All patients who achieved a partial metabolic response or complete metabolic response on iPET went on to achieve complete response at the end of treatment. R-CHOP-based therapy with iPET assessment appears to offer favourable outcomes, with radiotherapy and H. pylori eradication therapy implemented on a case-by-case basis.

Original language	English
Number of pages	8
Journal	British Journal of Haematology
DOIs	https://doi.org/10.1111/bjh.19470
Publication status	Published - 17 Apr 2024

Access to Document

10.1111/bjh.19470

Cite this

@article{7c680674adcc430c9ab3ea8d915cb8ff,

title = "Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study",

abstract = "Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) accounts for the majority of extra-nodal DLBCL. Even so, literature is lacking on early, localised presentations. We studied a cohort of patients with stage I disease, diagnosed between 2006 and 2018, from six centres between Australia, Canada and Denmark. Our goal was to characterise outcomes, review treatment and investigate the role of interim positron emission tomography (iPET). Thirty-seven eligible patients were identified. The median duration of follow-up was 42.2 months. All received chemoimmunotherapy with 91.9% (n = 34) given rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP). 35.1% (n = 13) underwent consolidative radiotherapy. Eighteen patients were H. pylori positive and 11 had the documentation of H. pylori eradication therapy. The 4-year progression-free survival and overall survival of R-CHOP was 88% (95% CI: 71–95) and 91% (95% CI: 75–97) respectively. All patients who achieved a partial metabolic response or complete metabolic response on iPET went on to achieve complete response at the end of treatment. R-CHOP-based therapy with iPET assessment appears to offer favourable outcomes, with radiotherapy and H. pylori eradication therapy implemented on a case-by-case basis.",

keywords = "DLBCL, extranodal lymphoma, gastric DLBCL, gastric lymphoma",

author = "Lewis, {Cameron S.} and Greta Joy and Paw Jensen and Allison Barraclough and Nunzio Franco and Dipti Talaulikar and Hawkes, {Eliza A.} and El-Galaly, {Tarec Christoffer} and Diego Villa and Michael Dickinson and Seymour, {John F.} and Cheah, {Chan Y.}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2024",

month = apr,

day = "17",

doi = "10.1111/bjh.19470",

language = "English",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Primary gastric diffuse large B-cell lymphoma

T2 - A multicentre retrospective study

AU - Lewis, Cameron S.

AU - Joy, Greta

AU - Jensen, Paw

AU - Barraclough, Allison

AU - Franco, Nunzio

AU - Talaulikar, Dipti

AU - Hawkes, Eliza A.

AU - El-Galaly, Tarec Christoffer

AU - Villa, Diego

AU - Dickinson, Michael

AU - Seymour, John F.

AU - Cheah, Chan Y.

PY - 2024/4/17

Y1 - 2024/4/17

N2 - Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) accounts for the majority of extra-nodal DLBCL. Even so, literature is lacking on early, localised presentations. We studied a cohort of patients with stage I disease, diagnosed between 2006 and 2018, from six centres between Australia, Canada and Denmark. Our goal was to characterise outcomes, review treatment and investigate the role of interim positron emission tomography (iPET). Thirty-seven eligible patients were identified. The median duration of follow-up was 42.2 months. All received chemoimmunotherapy with 91.9% (n = 34) given rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP). 35.1% (n = 13) underwent consolidative radiotherapy. Eighteen patients were H. pylori positive and 11 had the documentation of H. pylori eradication therapy. The 4-year progression-free survival and overall survival of R-CHOP was 88% (95% CI: 71–95) and 91% (95% CI: 75–97) respectively. All patients who achieved a partial metabolic response or complete metabolic response on iPET went on to achieve complete response at the end of treatment. R-CHOP-based therapy with iPET assessment appears to offer favourable outcomes, with radiotherapy and H. pylori eradication therapy implemented on a case-by-case basis.

AB - Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) accounts for the majority of extra-nodal DLBCL. Even so, literature is lacking on early, localised presentations. We studied a cohort of patients with stage I disease, diagnosed between 2006 and 2018, from six centres between Australia, Canada and Denmark. Our goal was to characterise outcomes, review treatment and investigate the role of interim positron emission tomography (iPET). Thirty-seven eligible patients were identified. The median duration of follow-up was 42.2 months. All received chemoimmunotherapy with 91.9% (n = 34) given rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP). 35.1% (n = 13) underwent consolidative radiotherapy. Eighteen patients were H. pylori positive and 11 had the documentation of H. pylori eradication therapy. The 4-year progression-free survival and overall survival of R-CHOP was 88% (95% CI: 71–95) and 91% (95% CI: 75–97) respectively. All patients who achieved a partial metabolic response or complete metabolic response on iPET went on to achieve complete response at the end of treatment. R-CHOP-based therapy with iPET assessment appears to offer favourable outcomes, with radiotherapy and H. pylori eradication therapy implemented on a case-by-case basis.

KW - DLBCL

KW - extranodal lymphoma

KW - gastric DLBCL

KW - gastric lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85190962037&partnerID=8YFLogxK

U2 - 10.1111/bjh.19470

DO - 10.1111/bjh.19470

M3 - Article

SN - 0007-1048

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -

Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this